Vaccine trials in melanoma—time for reflection
- 1 May 2009
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 6 (5) , 256-258
Abstract
The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.Keywords
This publication has 12 references indexed in Scilit:
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with VaccinesClinical Cancer Research, 2008
- Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced MelanomaJournal of Clinical Oncology, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Randomized Adjuvant Therapy Trials in Melanoma: Surgical and SystemicSeminars in Oncology, 2007
- Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGAnnals of Oncology, 2006
- Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 BlockadeThe Journal of Immunology, 2005
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004
- High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801Journal of Clinical Oncology, 2001
- Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2British Journal of Cancer, 1987